gemcitabine, carboplatin

DRUG3 trials

Sponsors

National University Hospital, Singapore, Hospital Authority, Hong Kong, Tianjin Medical University Cancer Institute and Hospital

Conditions

Lung NeoplasmsMetastatic Breast Cancer

Phase 2

Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer

CompletedNCT00212069

National University Hospital, SingaporeMetastatic Breast Cancer

Start: 2004-03-31End: 2013-04-30Target: 30Updated: 2013-12-11

Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small-cell Lung Cancer Before Surgery

Hospital Authority, Hong KongLung Neoplasms

Start: 2005-05-31End: 2007-02-28Target: 50Updated: 2010-07-07

Phase 3

Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer

Tianjin Medical University Cancer Institute and HospitalMetastatic Breast Cancer

Start: 2013-12-31End: 2016-12-31Target: 120Updated: 2015-12-22

Related Papers

A non-inferiority, phase III trial of gemcitabine plus capecitabine <i>versus</i> gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer

Therapeutic Advances in Medical Oncology2024-10-011 citations

A phase 3, multicenter, open, randomized controlled clinical study of gemcitabine plus capecitabine versus gemcitabine plus carboplatin in the first-line treatment for advanced triple-negative breast cancer.

Journal of Clinical Oncology2022-06-01